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Background: To evaluate the influence of parathyroid mass on the regulation of parathyroid hormone (PTH)
secretion, we investigated the relationship between the resected parathyroid gland in total parathyroidectomy and
the parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism.
Methods: From January 2009 to July 2014, 223 patients undergoing total parathyroidectomy were included. The
size and the weight of parathyroid gland were measured during the operation.
Results: 874 parathyroid glands were removed. A positive correlation was identified between the size and the
weight of resected parathyroid glands. We found that both the preoperative PTH and the reduction of PTH were
significantly correlated with the size and the weight of parathyroid glands in a positive manner. However, in the
subgroup of patients with PTH < 1000 pg/ml, no significant correlation was found.
Conclusions: Larger parathyroid gland secretes more PTH and high level of serum PTH usually indicated that
surgical removal might be required. However, since PTH levels could be influenced by the pharmaceutical drug, the
large size of parathyroid gland might be used as a much more appropriate guide that indicates the requirement of
surgery treatment even when the parathyroid hormone was less than 1000 pg/ml.
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Secondary hyperparathyroidism characterized by increased
secretion of PTH, is one of the major serious complications
of patients with chronic renal failure on long-term
hemodialysis [1]. In the course of secondary hyperparathyr-
oidism, parathyroid growth progresses gradually from dif-
fuse hyperplasia to nodular hyperplasia, and eventually to
formation of adenomas at advanced stages [2–4]. Several
clinical studies have documented that although PTH levels
can be suppressed by continuous treatment with phos-
phate binders, vitamin D analogs or calcimimetics [5–7],
the progressively reducing expression of calcium-sensing
receptors (CaSR) and vitamin D receptors (VDR) would* Correspondence: jwyang@njmu.edu.cn
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creativecommons.org/publicdomain/zero/1.0/result in resistance to treatment [8, 9], and, finally, requir-
ing parathyroidectomy (PTX) [10, 11]. Parathyroidectomy
was reported to become gradually necessary [12].
In the preoperative assessment of parathyroidectomy,
ultrasonography, scintigraphy, and positron emission
tomography scans are used to estimate the glandular size
and help plan the operative approach. However, imaging
studies are usually heavily operator-dependent, which
could even explain the wide variability in the reported
sensitivity (ranging from 30–80 %) for the detection of
abnormal parathyroid glands [13]. Thus, the surgeons
could not be entirely dependent on the imaging tech-
niques. Since the surgical exploration for parathyroid
glands and the surgical experience were crucial, success-
ful parathyroidectomy requires an understanding of both
the anatomy and the embryology of the parathyroid
glands. The surgeons need to learn more about thecle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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parathyroid hormone level. McCarron et al. have re-
ported that PTH induced by ethylene diamine tetraacetic
acid (EDTA) response was related to their total gland
size measured at the time of their PTX [14]. However,
some studies suggested that the altered quality of the
parathyroid mass and not only the increased parathyroid
mass might be responsible for non-controllable hyper-
parathyroidism in uremia [9]. The relationship between
parathyroid gland mass and the parathyroid hormone
levels remains uncertain. In this study, to evaluate the in-
fluence of parathyroid mass on the regulation of parathy-
roid hormone secretion, we investigated the relationship
between the parathyroid gland resected in total parathy-
roidectomy and the parathyroid hormone levels in
hemodialysis patients with secondary hyperparathyroidism.
Patients and methods
Selection of patients
We performed a retrospective analysis of a prospectively
collected cohort of consecutive adult patients who
underwent parathyroidectomy (PTX) treatment between
January 2009 and July 2014 in our institution. From
January 2009 to July 2014, 223 patients undergoing main-
tenance hemodialysis therapy with biochemical or clinical
evidence, or both, of secondary hyperparathyroidism were
referred to the second affiliated hospital of Nanjing medical
university for parathyroidectomy. Inclusion criteria were as
follows: 1) patients receiving dialysis for more than
6 months; 2) serum intact PTH level >500 pg/mL on two
or more occasions; and/or 3) patients with parathyroid
nodular or diffuse hyperplasia identified by ultrasound im-
aging or radioisotope scan; 4) patients with symptomatic
secondary hyperparathyroidism, such as bone and joint
pain, pathologic fractures, severe pruritus, restless legs syn-
drome and so on. In all patients, 4 h hemodialysis was
performed three times a week with bicarbonate dialysate
containing a 3.0 mEq/l calcium concentration. Exclusion
criteria included a history of parathyroidectomy, an un-
stable medical condition during the previous 30 days and
the cases with ectopic or residual parathyroid glands.
Study design
The study protocol was approved by the Ethics Commit-
tee of Nanjing Medical University. All patients gave their
consent to undergo PTX and participated in this study.
The written informed consent was obtained and docu-
mented in the legal medical record. In the preoperative
preparation, all cases had routine preoperative tests in-
cluding complete blood counts, biochemical tests, serum
electrolytes, coagulation screening, chest x-ray, electro-
cardiogram, heart Doppler ultrasound and so on. The
localization of parathyroid glands was evaluated by using
neck ultrasonography and parathyroid scintigraphy (termedTc-99 m 2 methoxy-isobutyl-isonitrile, 99mTc-MIBI). Des-
pite all this, identification of the exact location is still chal-
lenging. During the surgery, exploration for the hyperplasia
parathyroid glands was performed with the patient under
general anaesthesia, using a transverse collar incision. All
patients underwent total parathyroidectomy without auto-
transplantation. All resected parathyroid glands were mea-
sured, weighed and verified histologically. The volume of
each parathyroid gland (PTG) was estimated by using the
formula: a * b * c *π/6 mm3 (where a, b, and c are the di-
mensions of gland in millimeters).
Analysis of laboratory values
Blood routine tests were performed using an LH-750
Hematology Analyzer (Beckman Coulter, Inc., Fullerton,
CA). Biochemical indices, such as serum albumin, cal-
cium (Ca), phosphorus (P), and alkaline phosphatase
(ALP), were measured using an Automatic Biochemical
Analyzer (HITACHI 7080; Hitachi, Ltd, Tokyo, Japan).
Serum intact-parathyroid hormone (iPTH) levels were
measured using a UniCel DxI800 Access Immunoassay
System (Beckman Coulter, Inc., Fullerton, CA).
Statistical analyzes
Statistical analysis was done with SPSS 15 J for Windows
(SPSS, Chicago, IL, USA) to observe any significant differ-
ences. All data is shown as the mean ± S.D., unless otherwise
indicated. The relationship between the intact PTH levels
and the weight, the volume, the maximum diameter of para-
thyroid glands were investigated by Spearman’s rank correl-
ation coefficient. P-values <0.001 were considered significant.
Results
Clinical parameters of hemodialysis (HD) patients
undergoing parathyroidectomy
As shown in Table 1, the patients’ ages ranged from 16 to
70 years (average, 47.6 ± 11.11 years); They had undergone
maintenance hemodialysis therapy for 1 ~ 26 years (aver-
age, 8.3 ± 3.64 years). 126 patients were men and 97 were
women. The frequency distribution can be seen in Fig. 1.
Based on the criteria suggested by Gagne et al. [15],
surgical procedure was considered successful in all pa-
tients whose serum levels of iPTH dropped from mean
values of 1556.9 ± 879.27 pg/ml to 16.0 ± 44.76 pg/ml
(ANOVA, P < 0.001). More than 90 % decline in 24
h-postoperative PTH reliably predicts operative success.
Correlation of the weight with the size of parathyroid gland
In 223 patients, 874 glands were resected (Table 2). 214 pa-
tients had 4 parathyroid glands. Three glands were removed
in 8 patients. As shown in Fig. 2c, the sizes of parathyroid
gland were measured. By histopathology, all patients had the
diagnosis of nodular parathyroid hyperplasia. After oper-
ation, pruritus, bone pain and muscle weakness disappeared.
Table 1 Patient characteristics
Characteristic Patients (n = 223) Normal range
Age, years 47.6 ± 11.11 -
Gender (male/female) 126/97 -
Dialysis vintage, years 8.3 ± 3.64 -
Kt/V 1.4 ± 0.19 1.2 ~ 1.8
Calcium,mmol/L 2.51 ± 0.23 2.15 ~ 2.55 mmol/L
Phosphorus, mmol/L 2.11 ± 0.52 0.81 ~ 1.45 mmol/L
albumin-corrected calcium, mmol/L 2.47 ± 0.22 -
Albumin, g/dl 41.8 ± 4.37 39.7 ~ 49.4 g/L
calcium-phosphorus product 64.9 ± 17.50 -
Alkaline phosphatase (U/l) 405.5 ± 423.97 40 ~ 129 U/L
Intact PTH, pg/ml (preoperative) 1556.9 ± 879.27 12 ~ 88 pg/ml
Intact PTH, pg/ml (postoperative 1st day) 16.0 ± 44.76 12 ~ 88 pg/ml
Data are expressed as mean ± S.D
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resected glands for each patient. As shown in Fig. 2a and
b, a positive correlation was identified between the mass
and the weight of resected parathyroid glands (P < 0.001,
R = 0.967 for the volume; P < 0.001, R = 0.847 for the max-
imum diameter;).Fig. 1 Histogram for the frequency distribution of ages, dialysis vintages, PTH lev
product in 223 patients with secondary hyperparathyroidism. a: age distributio
vintages; c: distribution of cases according to PTH levels; d: distribution of cas
according to serum phosphorus levels; f: distribution of cases according to caCorrelation of the preoperative intact-PTH and the reduction
of intact-PTH with the size of parathyroid gland
Figures 3a, c and e show the correlation of serum intact
PTH with the volume, the weight, and the maximum diam-
eter of parathyroid gland (P < 0.001, R = 0.515; P < 0.001,
R = 0.511; P < 0.001, R = 0.437; respectively). A positiveels, albumin-corrected calcium, serum phosphorus and calcium-phosphorus
n patterns of patients; b: distribution of cases according to dialysis
es according to albumin-corrected calcium levels; e: distribution of cases
lcium-phosphorus product
Table 2 874 parathyroid glands identified at the primary operation in 223 patients for secondary hyperparathyroidism
Location No. of parathyroid glands The size (cm) The volume (cm3) The weight (g)
Right superior parathyroid gland 214 1.4 ± 0.57 (0.5–3.5) 0.35 ± 0.69 (0.01–4.24) 0.40 ± 0.65 (0.01–3.84)
Right inferior parathyroid gland 221 1.6 ± 0.48 (0.6–2.8) 0.60 ± 0.68 (0.06–3.27) 0.63 ± 0.69 (0.03–3.7)
Left superior parathyroid gland 221 1.5 ± 0.50 (0.4–3) 0.38 ± 0.60 (0.02–4.71) 0.40 ± 0.62 (0.01–4.55)
Left inferior parathyroid gland 218 1.6 ± 0.51 (0.5–3) 0.59 ± 0.81 (0.03–4.70) 0.67 ± 0.73 (0.04–4.32)
Data are expressed as mean ± S.D
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intact PTH after surgery and the volume, the weight, and
the maximum diameter of parathyroid gland (P < 0.001,
R = 0.513; P < 0.001, R = 0.509; P < 0.001, R = 0.436; re-
spectively). Therefore, the increased parathyroid mass
seems to secrete more PTH.
Then, we divided the patients into 3 subgroups: PTH
< 500 pg/ml, 500 ~ 1000 pg/ml and PTH> 1000 pg/ml. In
the subgroups of patients with PTH < 500 pg/ml and
PTH < 1000 pg/ml, no significant correlation was foundFig. 2 The relationship between the weight of parathyroid glands and th
between the total weight of the glands and their sizes. c: The parathyroid
for secondary hyperparathyroidismbetween PTH levels and parathyroid gland (Table 3).
Whereas, in the subgroups of patients with PTH
> 1000 pg/ml, serum intact PTH was correlated signifi-
cantly in a positive manner with the parathyroid gland
mass (P < 0.001, R = 0.338; P < 0.001, R = 0.396; P < 0.001,
R = 0.404; respectively).
Discussion
Chronic kidney disease–mineral and bone disorder
(CKD-MBD) is a growing health care concern associatedeir volume (n = 223). a and b: A positive correlation was found
glands identified and measured at the primary operation in patient
Fig. 3 The relationship between the levels of intact PTH and the parathyroid gland mass (n = 223). a, c and e: The level of iPTH was correlated
with the resected parathyroid gland mass. b, d and f: The reduction of iPTH was correlated with the resected parathyroid gland mass
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Table 3 Bivariate Pearson’s correlation analysis in three subgroups of hemodialysis patients with different serum PTH levels
PTH level
(pg/ml)
PTG Volume (cm3) PTG Weight (g) PTG Maximum Diameter (cm)
P value Spearman’s rho P value Spearman’s rho P value Spearman’s rho
<500 0.592 0.172 0.957 0.018 0.948 0.021
500 ~ 1000 0.297 0.140 0.186 0.178 0.248 0.156
>1000 0.000* 0.338 0.000* 0.396 0.000* 0.404
*P < 0.001, statistically significant
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ities, and increased risk of cardiovascular disease [16, 17].
As one of the most common abnormalities of CKD-MBD,
secondary hyperparathyroidism leads to nodular trans-
formation of the parathyroids in up to 75 % of cases
[18, 19]. Can the increased glandular mass be reduced?
Such a reduction would call for massive apoptosis to
take place in the parathyroids. However, there are no
known stimuli for apoptosis in the parathyroid cells [9].
Thus, poor efficacy of pharmaceutical drug in progres-
sive secondary hyperparathyroidism (SHPT) argues in
favour of parathyroidectomy [20–22]. The problem is
particularly severe in China. That’s because vitamin D ana-
logs and calcimimetics were unavailable in mainland China
during the study period. The most common drugs currently
used to treat secondary hyperparathyroidism in China were
calcium-based phosphorus binders and non-selective VDR
activator medications which may cause recurrent hypercal-
cemia and hyperphosphataemia.
Since the sensitivity of imaging procedures has been
reported to be lower in secondary hyperparathyroidism
than in primary hyperparathyroidism [23], even with the
use of combined neck ultrasonography and parathyroid
scintigraphy, bilateral surgical exploration with identifi-
cation of all glands is required. What’s more, since the
relatively small size of missed adenomatous glands could
always lead to a high rate of re-operation in whom major
anaesthesia risks are frequent, the surgeons need to get
a general preoperative assessment not only about the
localization but also the influence of parathyroid mass
on PTH secretion.
The relationship with the parathyroid gland and the
parathyroid hormone level was still uncertain until now.
Inaba et al. reported that serum bio-PTH but not intact
PTH correlated significantly in a positive manner with
the maximal diameter of the parathyroid gland [23].
Takatoshi et al. also demonstrated that the secretion of
PTH solely depends on the size of the parathyroid
glands [24]. However, some evidence hints that the para-
thyroid mass is to a large extent of less importance for
PTH secretion than the ‘quality’ of parathyroid mass.
The ‘content’ of the different noduli in severe parathyroid
hyperplasia is determining the PTH secretion [9]. Since
the mass of the parathyroid gland was usually determined
by ultrasonography in those studies, the ultrasonographytests are usually heavily operator-dependent and show a
wide variability. In our study, we evaluated the mass by
directly measuring the three dimensions of the resected
parathyroid glands in operation. We found that nodular
transformation of the parathyroids was up to 90 % in our
cases. Furthermore, a significantly positive correlation be-
tween the resected parathyroid gland and the intact serum
PTH was found. This data suggested that the larger para-
thyroid gland might secrete more intact PTH, confirming
that the size of a gland could be used as an indication for
surgical treatment. However, in the subgroup patients with
iPTH < 1000 pg/ml, no significant correlation was found.
The difference might lie in the previous treatment with
phosphate binders, vitamin D analogs or calcimimetics.
However, large evidence confirmed that PTH levels
might return to pre-treatment values when the treat-
ment is stopped [24–26]. What’s more, with the condi-
tion progress, medicine resistance could be a result of
the reducing expression of calcium-sensing receptors
(CaSR) and vitamin D receptors (VDR). Thus, we can-
not help wondering should we still use repeated non-
selective VDR activator in poorly controlled secondary
hyperparathyroidism. Our results suggested that PTH
levels might be influenced by the pharmaceutical drug
under manageable condition, whereas the size of para-
thyroid gland is to a large extent of more importance
on the regulation of PTH secretion. Therefore, the
large size of parathyroid gland might be used as a much
more appropriate guide that indicates the requirement
of surgery treatment even when the parathyroid hor-
mone was less than 1000 pg/ml.
Conclusion
In summary, nodular transformation of the parathyroids
was common in the patients with severe secondary
hyperparathyroidism. Generally, larger parathyroid gland
secretes more PTH and high level of serum PTH usually
indicated that surgical removal might be required. How-
ever, since PTH levels could easily be influenced by the
pharmaceutical drug, the large size of parathyroid gland
might be used as a much more appropriate guide that
indicates the requirement of surgery treatment.
Abbreviations
PTH: Parathyroid hormone; CaSR: Calcium-sensing receptors; VDR: Vitamin D
receptors; PTX: Parathyroidectomy; EDTA: Ethylene diamine tetraacetic acid;
Fang et al. BMC Nephrology  (2015) 16:82 Page 7 of 799mTc-MIBI: Tc-99 m methoxy-isobutyl-isonitrile; PTG: Parathyroid gland;
Ca: Calcium; P: Phosphorus; ALP: Alkaline phosphatase; iPTH: Intact-parathyroid
hormone; CKD-MBD: Chronic kidney disease–mineral and bone disorder;
SHPT: Secondary hyperparathyroidism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LF participated in the design of the study, collected data, made the figures
and table, analyzed and interpreted the data, drafted the manuscript. BT, DH
and MX performed the experiments, and collected data; MM helped to perform
the statistical analysis. JY conceived the study, drafted the manuscript, and
participated in coordination. All authors have given final approval of the version
to be published.
Acknowledgement
This work was supported by the Key Project of Science and Technology
Bureau of Jiangsu Province (No. BL2013037) to Junwei Yang.
Author details
1Center for Kidney Disease, 2nd Affiliated Hospital, Nanjing Medical
University, 262 Zhongshan North Road, Nanjing, Jiangsu Province, China.
2Department of General Surgery, 2nd Affiliated Hospital, Nanjing Medical
University, 262 Zhongshan North Road, Nanjing, Jiangsu Province, China.
Received: 29 September 2014 Accepted: 21 May 2015
References
1. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical
practice guideline for the management of secondary hyperparathyroidism
in chronic dialysis patients. Ther Apher Dial. 2008, 12(6):514–525.
2. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal
failure. J Am Soc Nephrol. 2000;11(6):1141–52.
3. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of
refractory secondary hyperparathyroidism. Kidney Int Suppl. 2002;80:155–60.
4. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A.
Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol.
2005;18(1):5–8.
5. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM,
et al. Doxercalciferol safely suppresses PTH levels in patients with secondary
hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
Am J Kidney Dis. 2004;43(5):877–90.
6. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG,
et al. Cinacalcet for secondary hyperparathyroidism in patients receiving
hemodialysis. N Engl J Med. 2004;350(15):1516–25.
7. Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, et al.
Self-reported symptoms in patients on hemodialysis with moderate to
severe secondary hyperparathyroidism receiving combined therapy with
cinacalcet and low-dose vitamin D sterols. Hemodial Int. 2012;16(2):188–97.
8. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K. Persistent
downregulation of calcium-sensing receptor mRNA in rat parathyroids
when severe secondary hyperparathyroidism is reversed by an isogenic
kidney transplantation. J Am Soc Nephrol. 2002;13(8):2110–6.
9. Lewin E, Olgaard K. Influence of parathyroid mass on the regulation of PTH
secretion. Kidney Int Suppl. 2006;102:S16–21.
10. Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K.
Mineral metabolism management in hemodialysis patients with secondary
hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J
Nephrol. 2011;33(5):427–37.
11. Yuan CM, Nee R, Narayan R, Abbott KC. Treatment of secondary
hyperparathyroidism with parathyroidectomy instead of cinacalcet: time to
pick the low-hanging fruit? Am J Kidney Dis. 2012;60(2):179–81.
12. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in
hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int.
2007;11(1):62–71.
13. Fuster D, Ybarra J, Ortin J, Torregrosa JV, Gilabert R, Setoain X, et al. Role of
pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients
with secondary hyperparathyroidism who are candidates for subtotal
parathyroidectomy. Eur J Nucl Med Mol Imaging. 2006;33(4):467–73.14. McCarron DA, Muther RS, Lenfesty B, Bennett WM. Parathyroid function in
persistent hyperparathyroidism: relationship to gland size. Kidney Int.
1982;22(6):662–70.
15. Gagne ER, Urena P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, et al. Short-
and long-term efficacy of total parathyroidectomy with immediate autografting
compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc
Nephrol. 1992;3(4):1008–17.
16. Yokoyama K, Taniguchi M, Fukagawa M. A Japanese approach for CKD-MBD.
Kidney Int Suppl (2011). 2013;3(5):451–6.
17. Goodman WG, Quarles LD. Development and progression of secondary
hyperparathyroidism in chronic kidney disease: lessons from molecular
genetics. Kidney Int. 2008;74(3):276–88.
18. Neyer U, Hoerandner H, Haid A, Zimmermann G, Niederle B. Total
parathyroidectomy with autotransplantation in renal hyperparathyroidism:
low recurrence after intra-operative tissue selection. Nephrol Dial Transplant.
2002;17(4):625–9.
19. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism:
pathogenesis, disease progression, and therapeutic options. Clin J Am Soc
Nephrol. 2011;6(4):913–21.
20. Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, et al.
Cinacalcet effectively reduces parathyroid hormone secretion and gland
volume regardless of pretreatment gland size in patients with secondary
hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5(12):2305–14.
21. Naranda J, Ekart R, Pecovnik-Balon B. Total parathyroidectomy with
forearm autotransplantation as the treatment of choice for secondary
hyperparathyroidism. J Int Med Res. 2011;39(3):978–87.
22. Ichii M, Ishimura E, Okuno S, Chou H, Kato Y, Tsuboniwa N, et al. Decreases
in parathyroid gland volume after cinacalcet treatment in hemodialysis
patients with secondary hyperparathyroidism. Nephron Clin Pract.
2010;115(3):c195–202.
23. Alexandrides TK, Kouloubi K, Vagenakis AG, Yarmenitis S, Spyridonidis T,
Vassilakos P, et al. The value of scintigraphy and ultrasonography in the
preoperative localization of parathyroid glands in patients with primary
hyperparathyroidism and concomitant thyroid disease. Hormones (Athens).
2006;5(1):42–51.
24. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, et al. A
randomized trial of sevelamer hydrochloride (RenaGel) with and without
supplemental calcium. Strategies for the control of hyperphosphatemia and
hyperparathyroidism in hemodialysis patients. Clin Nephrol. 1999;51(1):18–26.
25. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and
aluminum-free phosphate binder, lowers serum phosphorus and parathyroid
hormone. The RenaGel Study Group. Kidney Int. 1999;55(1):299–307.
26. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, et al. Controlled
trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone
in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis.
1998;32(2):238–46.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
